Radiopharmaceutical
Radiopharmaceutical Market Forecasts to 2030 - Global Analysis By Type (Diagnostic, Therapeutic and Other Types), Radioisotope, Source, Application, End User and By Geography
According to Stratistics MRC, the Global Radiopharmaceutical Market is accounted for $6.55 billion in 2024 and is expected to reach $13.06 billion by 2030 growing at a CAGR of 12.2% during the forecast period. A specific class of pharmaceutical products known as radiopharmaceuticals is made up of isotopes that are radioactive. The majority of applications for these substances in nuclear medicine are both therapeutic and diagnostic. When a patient is given radiopharmaceuticals for diagnostic purposes, the radiation they emit is recorded by imaging technologies like PET and SPECT, which produce fine-grained images of the body's internal organs and systems. Moreover, when used therapeutically, they are used to treat diseases like cancer, in which the radioactive component targets and destroys cancerous cells with radiation.
According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), radiopharmaceuticals play a critical role in the diagnosis and treatment of various diseases, including cancer, heart disease, and neurological disorders, by providing unique insights into the molecular and physiological processes within the body.
Market Dynamics:
Driver:
Growing rate of chronic illnesses
Chronic illnesses like cancer, heart disease, and neurological conditions are becoming more and more common worldwide. The incidence of cancer in particular has increased significantly, requiring more sophisticated diagnostic and treatment options. In order to improve treatment outcomes, radiopharmaceuticals provide non-invasive methods for early tumor detection and precise tumor targeting. Radiopharmaceuticals play a critical role in the identification of blockages and the evaluation of heart function in cardiovascular diseases. Additionally, they aid in the diagnosis of neurological disorders by identifying abnormalities and visualizing brain activity, which helps with conditions like Alzheimer's disease.
Restraint:
Exorbitant development and production costs
The process of creating and manufacturing radiopharmaceuticals is very expensive and complex. Complex infrastructure and technology, such as nuclear reactors or cyclotrons, which are costly to construct and operate, are needed to produce radioisotopes. In order to assure safety and efficacy, new radiopharmaceuticals must also undergo rigorous research and clinical trialing, which comes at a high cost. Furthermore, these exorbitant expenses may prevent new competitors from entering the market and may limit the amount of money available for innovation and research.
Opportunity:
Extension of medicinal uses
Though their use in diagnostic imaging has long predominated, there is increasing potential to extend the use of radiopharmaceuticals to therapeutic applications. Novel therapeutic approaches for a range of cancers and other illnesses are being made possible by developments in targeted radionuclide therapy (TRT). Radioligand therapy, for instance, has demonstrated potential in the treatment of neuroendocrine tumors and prostate cancer by directly delivering radioactive isotopes to cancer cells. Moreover, treatment options and patient outcomes can be greatly improved by extending the therapeutic uses of radiopharmaceuticals.
Threat:
Disruptions to the supply chain
The manufacturing and distribution of radiopharmaceuticals rely heavily on a delicate and intricate supply chain. Due to their short half-lives, a large number of radioisotopes used in radiopharmaceuticals require prompt and effective administration, transportation, and production. Any disruption in this supply chain be it from geopolitical unrest, natural disasters, technological malfunctions, or logistical difficulties, has the potential to affect patient care and cause shortages. Additionally, the supply of vital radioisotopes may be severely restricted by the shutdown of a cyclotron or nuclear reactor.
Covid-19 Impact:
The COVID-19 pandemic had a substantial effect on the market for radiopharmaceuticals, resulting in production and supply chain disruptions as a result of lockdowns, travel restrictions, and decreased manufacturing facility operational capacities. As healthcare systems gave priority to COVID-19 patients, the pandemic also caused a brief decline in non-essential medical procedures, such as diagnostic imaging and radiopharmaceutical therapies. However, the market also witnessed a spike in R&D endeavours focused on employing radiopharmaceuticals for COVID-19-associated diagnosis and therapies, underscoring the industry's flexibility and inventive capacity in emergency scenarios.
The Oncology segment is expected to be the largest during the forecast period
The radiopharmaceutical market is dominated by the oncology segment. The reason for this dominance is the high global cancer prevalence and the vital role that radiopharmaceuticals play in cancer treatment and diagnosis. In order to identify malignant lesions, gauge the extent of cancer spread, and track the efficacy of treatments, radiopharmaceuticals are widely used in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging. Furthermore, targeted cancer therapy is making greater use of therapeutic radiopharmaceuticals, such as radio labeled peptides and antibodies, which deliver radiation directly to tumor cells while minimizing damage to nearby healthy tissues.
The Cancer Research Institute segment is expected to have the highest CAGR during the forecast period
In the radiopharmaceutical market, the cancer research institute segment is anticipated to have the highest CAGR. The increased funding for cancer research and the creation of innovative radiopharmaceuticals for both therapeutic and diagnostic applications are the main drivers of this growth. Cancer research institutes are at the forefront of developing novel therapies and technologies, such as the highly precise targeting of particular cancer cells with radiopharmaceuticals. Moreover, large-scale research and clinical trials are made possible for these institutions by the significant funding they receive from government grants, private investments, and partnerships with pharmaceutical companies.
Region with largest share:
Due to factors like a high prevalence of chronic diseases, an advanced healthcare infrastructure, and growing investments in nuclear medicine, North America accounted for the largest share of the global radiopharmaceutical market. Due to its substantial R&D efforts and the presence of major market players, the United States in particular has a thriving market. Favourable government programs and reimbursement practices also encourage market expansion in the area. However, the distribution of market share may change in the future due to the quick growth of nuclear medicine applications worldwide and the rising use of radiopharmaceuticals in emerging economies.
Region with highest CAGR:
The radiopharmaceutical market is expected to grow at the highest CAGR in the European region. The region's market is expanding due to factors like rising healthcare infrastructure investments, a growing use of nuclear medicine techniques for diagnostic and therapeutic purposes, and an increase in the prevalence of chronic illnesses like cancer and neurological disorders. Furthermore, the market is expanding due to favourable reimbursement policies, technological advancements in the production of radiopharmaceuticals, and partnerships between pharmaceutical companies and research institutes.
Key players in the market
Some of the key players in Radiopharmaceutical market include Cardinal Health Inc., Eli Lilly and Company, General Electric Company, Covidien Plc, Iso-Tex Diagnostics, Inc, Bayer AG, IBA Radiopharma Solutions, Lantheus Holdings, Inc., Monrol Nuclear Products,Inc, Siemens AG, Novartis AG, BWX Technologies, Inc., Jubilant Pharmova Limited, Nordion,Inc., Curium Pharma and Positron Corporation.
Key Developments:
In April 2024, Bayer AG has entered into a long-term supply agreement for renewable energy with Wuppertaler Stadtwerke (WSW), the public utility company of Wuppertal in North Rhein-Westphalia, Germany. Under the agreement, WSW will provide Bayer with over 120 GWh of wind and/or solar power from German wind and solar parks annually, equivalent to the electricity consumption of approximately 30,000 households.
In January 2024, Cardinal Health Inc. announced an agreement to buy Specialty Networks for $1.2 billion in cash, as the drug distributor and medical products maker looks to enhance its data analytics capabilities. The company said the acquisition expands its offering in therapeutic areas and increases its data and research opportunities with biopharmaceutical manufacturers.
In April 2024, Bayer AG has entered into a long-term supply agreement for renewable energy with Wuppertaler Stadtwerke (WSW), the public utility company of Wuppertal in North Rhein-Westphalia, Germany. Under the agreement, WSW will provide Bayer with over 120 GWh of wind and/or solar power from German wind and solar parks annually, equivalent to the electricity consumption of approximately 30,000 households.
Types Covered:
• Diagnostic
• Therapeutic
• Other Types
Radioisotopes Covered:
• Yttrium-90
• Thallium-201
• Technetium-99
• Strontium -89
• Samarium-153
• Rubidium-82
• Rhenium-186
• Radium-223
• Palladium - 103
• Leutetium-177
• Iridium - 192
• Iodine-131
• Iodine-125
• Iodine-123
• Indium-111
• Holmium-166
• Gallium-68
• Gallium-67
• Fluorine-18
• Fludeoxyglucose - (18F-FDG)
• Erbium-169
• Cesium-131
• Actinium-225
• Other Radiosotopes
Sources Covered:
• Nuclear Reactors
• Cyclotrons
Applications Covered:
• Thyroid
• Theranostics
• Oncology
• Neurology
• Neuroendocrinology
• Nephrology
• Lymphoma
• Inflammation
• Gastroenterology
• Cardiology
• Other Applications
End Users Covered:
• Hospitals and Clinics
• Ambulatory Surgical Centers
• Cancer Research Institute
• Diagnostic Imaging Centers
• Medical Imaging Centers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Radiopharmaceutical Market, By Type
5.1 Introduction
5.2 Diagnostic
5.2.1 Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
5.2.2 Positron Emission Tomography (PET) Radiopharmaceuticals
5.3 Therapeutic
5.3.1 Alpha Emitters
5.3.2 Beta Emitters
5.3.3 Brachytherapy Isotopes
5.4 Other Types
6 Global Radiopharmaceutical Market, By Radioisotope
6.1 Introduction
6.2 Yttrium-90
6.3 Thallium-201
6.4 Technetium-99
6.5 Strontium -89
6.6 Samarium-153
6.7 Rubidium-82
6.8 Rhenium-186
6.9 Radium-223
6.10 Palladium - 103
6.11 Leutetium-177
6.12 Iridium - 192
6.13 Iodine-131
6.14 Iodine-125
6.15 Iodine-123
6.16 Indium-111
6.17 Holmium-166
6.18 Gallium-68
6.19 Gallium-67
6.20 Fluorine-18
6.21 Fludeoxyglucose - (18F-FDG)
6.22 Erbium-169
6.23 Cesium-131
6.24 Actinium-225
6.25 Other Radiosotopes
7 Global Radiopharmaceutical Market, By Source
7.1 Introduction
7.2 Nuclear Reactors
7.3 Cyclotrons
8 Global Radiopharmaceutical Market, By Application
8.1 Introduction
8.2 Thyroid
8.3 Theranostics
8.4 Oncology
8.5 Neurology
8.6 Neuroendocrinology
8.7 Nephrology
8.8 Lymphoma
8.9 Inflammation
8.10 Gastroenterology
8.11 Cardiology
8.12 Other Applications
9 Global Radiopharmaceutical Market, By End User
9.1 Introduction
9.2 Hospitals and Clinics
9.3 Ambulatory Surgical Centers
9.4 Cancer Research Institute
9.5 Diagnostic Imaging Centers
9.6 Medical Imaging Centers
9.7 Other End Users
10 Global Radiopharmaceutical Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Cardinal Health Inc.
12.2 Eli Lilly and Company
12.3 General Electric Company
12.4 Covidien Plc
12.5 Iso-Tex Diagnostics, Inc
12.6 Bayer AG
12.7 IBA Radiopharma Solutions
12.8 Lantheus Holdings, Inc.
12.9 Monrol Nuclear Products,Inc
12.10 Siemens AG
12.11 Novartis AG
12.12 BWX Technologies, Inc.
12.13 Jubilant Pharmova Limited
12.14 Nordion,Inc.
12.15 Curium Pharma
12.16 Positron Corporation
List of Tables
1 Global Radiopharmaceutical Market Outlook, By Region (2022-2030) ($MN)
2 Global Radiopharmaceutical Market Outlook, By Type (2022-2030) ($MN)
3 Global Radiopharmaceutical Market Outlook, By Diagnostic (2022-2030) ($MN)
4 Global Radiopharmaceutical Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2022-2030) ($MN)
5 Global Radiopharmaceutical Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2022-2030) ($MN)
6 Global Radiopharmaceutical Market Outlook, By Therapeutic (2022-2030) ($MN)
7 Global Radiopharmaceutical Market Outlook, By Alpha Emitters (2022-2030) ($MN)
8 Global Radiopharmaceutical Market Outlook, By Beta Emitters (2022-2030) ($MN)
9 Global Radiopharmaceutical Market Outlook, By Brachytherapy Isotopes (2022-2030) ($MN)
10 Global Radiopharmaceutical Market Outlook, By Other Types (2022-2030) ($MN)
11 Global Radiopharmaceutical Market Outlook, By Radioisotope (2022-2030) ($MN)
12 Global Radiopharmaceutical Market Outlook, By Yttrium-90 (2022-2030) ($MN)
13 Global Radiopharmaceutical Market Outlook, By Thallium-201 (2022-2030) ($MN)
14 Global Radiopharmaceutical Market Outlook, By Technetium-99 (2022-2030) ($MN)
15 Global Radiopharmaceutical Market Outlook, By Strontium -89 (2022-2030) ($MN)
16 Global Radiopharmaceutical Market Outlook, By Samarium-153 (2022-2030) ($MN)
17 Global Radiopharmaceutical Market Outlook, By Rubidium-82 (2022-2030) ($MN)
18 Global Radiopharmaceutical Market Outlook, By Rhenium-186 (2022-2030) ($MN)
19 Global Radiopharmaceutical Market Outlook, By Radium-223 (2022-2030) ($MN)
20 Global Radiopharmaceutical Market Outlook, By Palladium - 103 (2022-2030) ($MN)
21 Global Radiopharmaceutical Market Outlook, By Leutetium-177 (2022-2030) ($MN)
22 Global Radiopharmaceutical Market Outlook, By Iridium - 192 (2022-2030) ($MN)
23 Global Radiopharmaceutical Market Outlook, By Iodine-131 (2022-2030) ($MN)
24 Global Radiopharmaceutical Market Outlook, By Iodine-125 (2022-2030) ($MN)
25 Global Radiopharmaceutical Market Outlook, By Iodine-123 (2022-2030) ($MN)
26 Global Radiopharmaceutical Market Outlook, By Indium-111 (2022-2030) ($MN)
27 Global Radiopharmaceutical Market Outlook, By Holmium-166 (2022-2030) ($MN)
28 Global Radiopharmaceutical Market Outlook, By Gallium-68 (2022-2030) ($MN)
29 Global Radiopharmaceutical Market Outlook, By Gallium-67 (2022-2030) ($MN)
30 Global Radiopharmaceutical Market Outlook, By Fluorine-18 (2022-2030) ($MN)
31 Global Radiopharmaceutical Market Outlook, By Fludeoxyglucose - (18F-FDG) (2022-2030) ($MN)
32 Global Radiopharmaceutical Market Outlook, By Erbium-169 (2022-2030) ($MN)
33 Global Radiopharmaceutical Market Outlook, By Cesium-131 (2022-2030) ($MN)
34 Global Radiopharmaceutical Market Outlook, By Actinium-225 (2022-2030) ($MN)
35 Global Radiopharmaceutical Market Outlook, By Other Radiosotopes (2022-2030) ($MN)
36 Global Radiopharmaceutical Market Outlook, By Source (2022-2030) ($MN)
37 Global Radiopharmaceutical Market Outlook, By Nuclear Reactors (2022-2030) ($MN)
38 Global Radiopharmaceutical Market Outlook, By Cyclotrons (2022-2030) ($MN)
39 Global Radiopharmaceutical Market Outlook, By Application (2022-2030) ($MN)
40 Global Radiopharmaceutical Market Outlook, By Thyroid (2022-2030) ($MN)
41 Global Radiopharmaceutical Market Outlook, By Theranostics (2022-2030) ($MN)
42 Global Radiopharmaceutical Market Outlook, By Oncology (2022-2030) ($MN)
43 Global Radiopharmaceutical Market Outlook, By Neurology (2022-2030) ($MN)
44 Global Radiopharmaceutical Market Outlook, By Neuroendocrinology (2022-2030) ($MN)
45 Global Radiopharmaceutical Market Outlook, By Nephrology (2022-2030) ($MN)
46 Global Radiopharmaceutical Market Outlook, By Lymphoma (2022-2030) ($MN)
47 Global Radiopharmaceutical Market Outlook, By Inflammation (2022-2030) ($MN)
48 Global Radiopharmaceutical Market Outlook, By Gastroenterology (2022-2030) ($MN)
49 Global Radiopharmaceutical Market Outlook, By Cardiology (2022-2030) ($MN)
50 Global Radiopharmaceutical Market Outlook, By Other Applications (2022-2030) ($MN)
51 Global Radiopharmaceutical Market Outlook, By End User (2022-2030) ($MN)
52 Global Radiopharmaceutical Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
53 Global Radiopharmaceutical Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
54 Global Radiopharmaceutical Market Outlook, By Cancer Research Institute (2022-2030) ($MN)
55 Global Radiopharmaceutical Market Outlook, By Diagnostic Imaging Centers (2022-2030) ($MN)
56 Global Radiopharmaceutical Market Outlook, By Medical Imaging Centers (2022-2030) ($MN)
57 Global Radiopharmaceutical Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
